Showing posts with label Malignant. Show all posts
Showing posts with label Malignant. Show all posts

Saturday, June 15, 2013

Malignant cancers

Mesothelioma: Malignant cancersskip to main | skip to sidebarMesotheliomaMesothelioma information, mesothelium, mesothelioma symptoms, mesothelioma prognosis

PagesHome Malignant cancersMalignant cancers
Malignant pleural mesothelioma: biology and diagnostic

Abstract
Malignant pleural mesothelioma (MPM) is increasing concern about cancer incidence and poor prognosis, although real progress in caring for patients. The diagnosis is usually made on the modern stage, when radical treatment is no longer available. It undergoes a significant increase in survival in MPM, including the early diagnosis of the disease. Biologically, a number of potential tumor markers soluble, including mesothelia and osteopontin, have been proposed to assist the diagnosis, but none have been approved to date. Mesothelin, measured in blood and pleural fluid appears to be the most interesting candidate. However, although this marker has a decent symptomatic and prognostic importance, its high specificity for the subtype of epithelioid mesothelioma (most often) restricts its use in practice. Other molecules are somewhat interesting, sometimes, despite good sensitivity, especially because of their low diagnostic specificity. Finally, available data do not argue for routine use in biology in the diagnosis of MPM, thoracoscopy, and the remaining histology verified. We must continue our search and evaluation of soluble mesothelia tumor markers in clinical trials.
Malignant cancers
Abstract
Another malignant pleural mesothelioma breast cancer: biology and diagnosis
Malignant pleural mesothelioma (MPM) is a serious issue because of the increasing incidence and poor prognosis of its in the world although the real improvement of disease management. The majority of patients are diagnosed late throughout the disease, when treatment is the more radical variant of this year. Earlier this year, it was necessary to significantly increase survival of patients diagnosed with MPM. Some of the soluble markers, including soluble Mesothelin, and osteopontin, have been proposed previously calculated for any diagnosis of MPM has not been approved yet. Soluble Mesothelin, estimated blood and pleural effusion, it seems that the most promising candidate. However, even if he has a decent diagnostic and prognostic significance, it is quite a special epithelioid subtype, one of the most common mesothelioma, Malthus imitating its used in practice. Although sometimes a good sensitivity, etc., as possible marker's osteopontin has a low specificity because of the diagnosis of MPM is a little interesting. In conclusion, the present data do not justify the routine use of biology for MPM diagnosis does suggest the need for continued evaluation of soluble Mesothelin injustement to clinical studies and the search for potential tumor markers other.
Newer PostOlder PostHomeSearchFollowersBlog Archive? 2012(30)? April(26)Cancer compensationMalignant cancersAsbestos exposure and cancerConsequences of cancer MesotheliomaCancer unknown primaryBenign mesothelioma of the uterusBenign MesotheliomaDiagnosis mesotheliomaWhat is asbestosDefine mesotheliomaPulmonary lobectomyALIMTAOncolytic virusesCancer fighting virusCancer glossaryPulmonary pleurisyFactors that increase the risk of cancerMesothelioma of the pleuraPLEURAL CANCERSkin cancer in young adultsOccupational disease workers compensationOccupational diseasesEmployer ResponsibilitiesOccupational healthcareWhat is pneumoconiosisOccupational cancer ?  March(2) ?  February(2) ?  2011(14) ?  December(9) ?  May(5)Popular PostsTreatment MesotheliomaTreatment Mesothelioma Most successful mesothelioma treatment methodology up to now After the diagnosis of mesothelioma cancer therapies...Alternative Treatments for MesotheliomaAlternative Treatments for Mesothelioma Natural Treatments Intended For Mesothelioma Cancer Mesothelioma , lung cancer can be determined ...Peritoneal Mesothelioma Cancer Peritoneal Mesothelioma Cancer Summary of treatment of Mesothelioma After the diagnosis of mesothelioma cancer the standard treatment is ...Mesomark Blood TestMesomark Blood Test Mesothelioma - Blood Test for Cancer Diagnosis Evidence so far in our measurements suggest that the serum SMRPs can ...Cancer in Abdominal CavityCancer in Abdominal Cavity Mesothelioma affects the body cavity Mesothelioma is a cancer of the mesothelium , which is the membrane that... Copyright © Mesothelioma

View the original article here

Thursday, May 30, 2013

The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos

Main Category: Asbestos / Mesothelioma
Article Date: 19 Mar 2012 - 0:00 PST Current ratings for:
The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos
not yet rated4 stars
Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, radiotherapy and chemotherapy. There are two main approaches, and controversy has existed about which approach is superior. One is called extrapleural pnemonectomy (EPP), a very extensive surgery where surgeons remove the entire diseased lung, lung lining (pleura), part of the membrane covering the heart (pericardium) and part of the diaphragm. Another approach involves a less extensive surgery called pleurectomy/decortication (P/D), where surgeons remove part of the lining around the lungs, potentially part, but not all of the lung, and potentially part of the diaphragm and/or membrane around the heart. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology concludes that the P/D method had better results for patients in a recent analysis.

According to the study, "EPP resulted in higher mortality and morbidity than P/D, and P/D resulted in significantly better survival in our experience as in others." The authors, "propose that P/D becomes the standard surgical procedure offered as part of multi-modality therapy in malignant pleural mesothelioma."

Until recently, EPP was the considered the standard of treatment. But this latest study along with other recent research seems to point to P/D becoming the new standard of treatment. Dr. Michael Weyant, thoracic surgeon and assistant professor at the University of Colorado, wrote an editorial in the April JTO about this topic. He concludes that, "the results of the current study by Lang-Lazdunksi et al provide additional data that should lead us to consider P/D in all trials of treatment for MPM. It is too early based on this data to completely abandon EPP altogether as there may be patient subsets where the potential reward outweighs the risks of the procedure."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our asbestos / mesothelioma section for the latest news on this subject. The lead author of this work is Dr. Loïc Lang-Lazdunski, IASLC member co-authors include Dr. David Landau and Dr. James Spicer, all at King's College London-Division of Cancer Studies.
International Association for the Study of Lung Cancer Please use one of the following formats to cite this article in your essay, paper or report:

MLA

International Association for the Study of Lung Ca. "The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos." Medical News Today. MediLexicon, Intl., 19 Mar. 2012. Web.
29 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Wednesday, May 29, 2013

What Is Mesothelioma? What Is Malignant Mesothelioma?

Editor's Choice
Main Category: Asbestos / Mesothelioma
Also Included In: Lung Cancer;  Respiratory / Asthma;  Cancer / Oncology
Article Date: 16 Nov 2011 - 0:00 PST Current ratings for:
What Is Mesothelioma? What Is Malignant Mesothelioma?
5 starsnot yet rated
Mesothelioma, more precisely known as malignant mesothelioma is a rare cancer of the mesothelial cells, most commonly those in the lining that covers the lungs (pleura). Mesothelial cells exist in the lining (membrane) that covers the outer surface of our body organs. The majority of people with mesothelioma have been exposed to asbestos at some time during their life.

Doctors usually divide mesothelioma into three types: Pleural mesothelioma - affects the pleura, the lining surrounding the lungs. This is the most common form.Peritoneal mesothelioma - the cancer attacks the lining of the abdomen, the peritoneum. This is the second most common form.Pericardial mesothelioma - the cancer attacks the protective layer covering the heart. This is the rarest form.All three forms of mesothelioma are nearly always caused by asbestos exposure.

Mesothelioma is an aggressive form of cancer. For the majority of patients there is no cure. Doctors usually focus on improving the quality of life as the disease progresses - making the patient as comfortable as possible.

In the United Kingdom, approximately 2,000 patients are diagnosed with mesothelioma annually. According to the CDC (Centers for Disease Control and Prevention), mesothelioma kills over 2,700 people in the USA every year. According to the Mesothelioma register, deaths from this type of cancer rose more than tenfold from 1969 to 2009 in the UK. About four-fifths of all deaths are among men.

According to Medilexicon's medical dictionary, mesothelioma is:

"A rare neoplasm derived from the lining cells of the pleura or peritoneum that grows as a thick sheet covering the viscera and is composed of spindle cells or fibrous tissue that may enclose glandlike spaces lined by cuboidal cells."
A symptom is something the patient feels and describes; while a sign is something other people can see, including doctors and nurses. For example, a symptom may be pain, while a sign could be a rash.

Exposure to asbestos and asbestos dust can take up to thirty years to show symptoms. Often, patients are diagnosed when the disease is already advanced. Outcomes depend on how early the malignancy can be diagnosed.

Mesothelioma signs and symptoms vary, depending on where in the body the cancer is.

Pleural mesothelioma (tissue surrounding the lungs) Shortness of breathCoughing, often painfulUnexpected and unexplained loss of weightPain under the rib cageSometimes lumps may be detectable under the skin in the chest areaLower back painDiscomfort in the side of the chestExhaustionSome people may experience sweating, fever, or difficulty swallowingPeritoneal mesothelioma (lining in the abdomen) Unexplained weight lossPain in the abdomenSwelling in the abdomenLumps in the abdomenNausea, some patients may experience vomitingPericardial mesothelioma (lining in the heart area) Low blood pressureShortness of breathFluid retention (edema), often in the legsHeart palpitationsFatigue, extreme after light exertionChest painExperts say that prolonged exposure to asbestos particles is the primary cause of mesothelioma. The risk of developing the disease is closely linked to asbestos particle dosage - i.e. the likelihood of developing mesothelioma is directly proportional to how long a person was exposed, and how much they inhaled.

People in jobs where exposure to asbestos fibers are common have the highest risk of developing the disease. Asbestos was commonly used for insulation, soundproofing, fireproofing, roofing, and ironing board covers.

Industries that may have involved asbestos exposure for some of their workpeople include constructions sites, steel mills, shipyards, oil refineries and power plants.

When the asbestos particles or fibers are inhaled or ingested, they build up in the lining of the abdomen, chest or lungs. This accumulation considerably increases the chances of cancerous cells developing.

When asbestos is damaged and particles or fibers are released into the air, the environment can become hazardous to human health. The fibers can be breathed in or swallowed, they get embedded in tissue, and eventually lead to mesothelioma.

Asbestos is a group of minerals that occur naturally. They exist as fibers or bundles. These fibers may be found in soil or rocks and exist in many parts of the world naturally. Asbestos is made of silicon, oxygen and some other elements.

There are two principle types of asbestos fibers: Serpentine asbestos - this is the most common type used in industry. It is known as white asbestos, or chrysotile. The fibers are curly.Amphibole asbestos - these include anthophyllite, amosite, actinolite, crocidolite, and tremolite. The fibers are straight, like needles. This type of asbestos, particularly crocidolite, is considered to be more likely to cause cancer. However, even serpentine asbestos has been linked to cancer.Although asbestos is much less used today than it used to be, exposure is still possible, and continues to be a serious problem. Older materials containing asbestos can break down, releasing a dust composed of tiny particles than can be inhaled or ingested. Exposure can occur when older buildings are demolished or renovated.

Even family members who never set foot in a working environment that contained asbestos can be exposed. The fibers can be carried home in the workers clothing, and then breathed in by other members of the household.

Asbestos can also be swallowed, as may occur when water flows through asbestos cement pipes. Inhaled asbestos can be coughed up, and then swallowed (when the person swallows the saliva).

WHO (World Health Organization) in 2005 said that approximately 125 million people globally were exposed to asbestos at work in that year, despite their employers having known about the link to cancer and other lung diseases for over six decades. Most work-related exposure today occurs in developing nations.

In much rarer cases, mesothelioma may be linked to irradiation, the inhalation of eronite or some other fibrous silicate, and intrapleural thorium dioxide (Thorotrast - a suspension containing radioactive particles, used in X-ray diagnostics during the 1930s and 1940s, and even in the 1950s in some nations including the USA). Some experts believe that SV40 (simian virus 40) could be involved in the development of the disease. A digital chest x-ray of advanced malignant mesothelioma
Digital chest x-ray of advanced malignant mesothelioma (on left) After asking certain diagnostic questions, such as the patient's symptoms, where he/she has worked, medical history and family history, and carrying out a physical examination, the doctor may order some imaging scans. This could be a CT scan or X-ray of the abdomen or chest to rule out any abnormalities. Usually, depending on the results of the scans, further testing may be recommended.

Biopsy - some tissue is surgically removed so that it can be examined in the laboratory under a microscope. To determine whether a patient has mesothelioma, this will have to be done. How the biopsy is carried out depends on which part of the body is targeted:

Targeting either the chest or abdominal area
Fine-needle aspiration - a small needle is inserted into the abdomen and chest and some fluid or piece of tissue is removedTargeting the chest area
Thoracoscopy - the surgeon inserts a thoracoscope through a small incision between the patient's ribs. A thoracoscope is an endoscope for examination of the chest cavity - it is a tube with a small camera at the end. The surgeon removes a piece of tissue with special tools.Thoracotomy - in this surgical intervention, the chest is opened between the ribs so that the surgeon can see the target area and check for signs of cancer. Some tissue may also be removed and sent to the laboratory for testing.Targeting the abdominal area
Laparoscopy - a small incision is made in the abdominal wall, a laparoscope is inserted through the incision into the abdomen, where the surgeon can have a look. The laparoscope is a long tube with a camera at the end. With specialized tools, tissue samples can be removed.Laparotomy - the surgeon opens the abdomen and has a look. Sometimes tissue samples may be removed and sent to the lab.When the tissue or fluid sample is viewed through a microscope, the pathologist can tell whether there is malignancy (e.g. malignant mesothelioma), what types of cells are involved, and how advanced the cancer is. How advanced a cancer is, defining it, is called Staging.

Staging - in medicine, specifically cancer, staging is the process of carrying out tests and examinations to determine the extent of the cancer, how advanced it is, and whether it has metastasized (spread from its original site to other parts of the body).

As soon as mesothelioma has been confirmed (diagnosed), other tests will be ordered to help determine the stage of the cancer. These may include such scans as CT, MRI (magnetic resonance imaging), PET (positron emission tomography), or a chest X-ray. What type of scan is used depends on several different factors.

When all the data is gathered together, the health care professional will assign the cancer a stage. The staging below is for pleural mesothelioma (lungs): Stage 1 - the cancer is localized. It is still inside the lining around the lung. It has not spread out.Stage 2 - the cancer may have spread to a lung or the diaphragm.Stage 3 - the cancer may have reached the lymph nodes, and possibly other parts of the chestStage 4 - the cancer has either spread more extensively in the chest, or may even have reached other parts of the body far from the original site. It may have reached other lymph nodes, or even the brain.The treatment the doctor will recommend depends on several factors, including: Where the cancer isThe stage of the cancer (how advanced it is)The patient's general health and ageSadly, this type of cancer is usually spotted when it has been progressing for a while. Add to this the fact that mesothelioma is usually an aggressive type of cancer, and you have two reasons why so few patients are cured.

If the cancer is very advanced, the tumor(s) can no longer be surgically removed. The only option left, in many cases, is to control the cancer, try to slow down its progress, and focus on making the patient as comfortable as possible.

It is vital that the medical team explains all the options to the patient - including their pros and cons - and if necessary, to his/her loved ones and/or caregivers. Fighting the cancer aggressively may mean enduring very unpleasant side effects, while just focusing on pain and quality of life for the remaining time, might be a better option. This is something the patient needs to discuss thoroughly with the medical team, and perhaps family members or close friends.

Surgery - this means removing tumors by surgery. Surgery is usually only an option during the early stages of the cancer. It may remove the whole cancer, or at least reduce some symptoms and slow it down. Fluid accumulation in the lung area - surgery may be recommended if there is fluid accumulation in the chest, resulting in breathing difficulties. The fluid is drained with a tube or catheter. A drug may be injected into the chest to stop a recurrence of fluid build-up. Drugs, such as tetracycline, talc powder, or bleomycin are instilled inside the space between the two layers of tissue lining the lungs (pleura); this causes inflammation, making the two pleura tack together, leaving no space for fluid build-up. Treatment for preventing this type of fluid build-up is called pleurodesis.Pleurectomy or peritonectomy - the lining around the lungs or abdominal cavity may be surgically removed. The aim is to relieve mesothelioma symptoms.Debulking - removing as much of the tumor as possible, if it is not possible to remove all of it.Removing a lung - signs and symptoms may be relieved if the surgeon removes the affected lung and its surrounding tissue. This will be followed by radiotherapy.Chemotherapy - if tumors cannot be surgically removed, chemotherapy may help shrink them, as well as to slow down their progress. Neoadjuvant chemotherapy may also be recommended - administering chemotherapy before surgery which can make it easier to remove a tumor. Chemotherapy used after surgery to try to prevent recurrence is called adjuvant chemotherapy.

Radiotherapy - also known as radiation therapy. For those with pleural mesothelioma, it may help relieve symptoms. Radiotherapy is sometimes administered to prevent metastasis after biopsy or surgery.

A Radiation Therapy Linear Accelerator for cancer treatment
Radiation therapy can help relieve symptoms

Clinical trials - human studies using novel treatment methods. The patient should discuss what the trial is about, as well as what to expect realistically, thoroughly with the doctor.

Cancer is a very unpredictable disease, and providing an accurate prognosis is not easy.

In general, prognoses for patients with mesothelioma are not encouraging. Malignant mesothelioma is a very aggressive type of cancer; it also has a long latency period. In the majority of cases, the disease is only detected when it is already in an advanced stage.

In most cases, survival for pleural malignant mesothelioma after diagnosis is no more than one or two years. The patient needs to bear in mind that there are exceptions, and new treatments are being researched and appear all the time.

Written by Christian Nordqvist

Original article date: 3 March 2009. Article updated: 16 November 2011.
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our asbestos / mesothelioma section for the latest news on this subject. Sources: The National Health Service (UK), CDC (Centers for Disease Control and Prevention, USA), WHO (World Health Organization), NIH (National Institutes of Health, USA), HSA (Health and Safety Executive, UK). Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Nordqvist, Christian. "What Is Mesothelioma? What Is Malignant Mesothelioma?." Medical News Today. MediLexicon, Intl., 16 Nov. 2011. Web.
29 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


posted by vipinpatel on 11 May 2013 at 9:28 pm

advanced cancer is nothing to cure, but who have been doing job in this prolonged exposure to asbestos particles . whom should be checking yearly. who should wear mask daily

| post followup | alert a moderator |


posted by Ishak Idris on 17 Nov 2012 at 7:24 am

Treatments include surgery, radiation therapy or chemotherapy or a combination of these treatments. Nice blog and good article

| post followup | alert a moderator |


posted by Ishak Idris on 17 Nov 2012 at 6:42 am

Although mesothelioma Benin to treat a lot easier than the malignant form of cancer known. Many cases have been treated and cured.
Protect yourself from mesothelioma

| post followup | alert a moderator |


'What Is Mesothelioma? What Is Malignant Mesothelioma?'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

First Analysis Of IASLC Malignant Pleural Mesothelioma Database

Main Category: Asbestos / Mesothelioma
Article Date: 17 Oct 2012 - 1:00 PST Current ratings for:
First Analysis Of IASLC Malignant Pleural Mesothelioma Database
not yet ratednot yet rated
The International Mesothelioma Interest Group (IMIG) staging system has been widely used, however, widespread concerns exist about the validity of the current malignant pleural mesothelioma (MPM) staging system. Concerns include that the system is derived from analysis of small, retrospective surgical series; it can be difficult to apply to clinical staging; and uses descriptors for lymph node involvement, which may not be relevant to MPM. Therefore, in collaboration with IMIG, the International Association for the Study of Lung Cancer (IASLC) has decided to update the staging system for MPM by developing a large international database.

A study, published in the November 2012 issue of the IASLC'S Journal of Thoracic Oncology, reports the current staging system by and large appropriately distinguishes among T and N categories and overall stages but also highlights areas for potential revision.

The study looked at 3,101 patients from 15 centers in four continents. The current data still represents mainly surgically treated patients. The authors report that current T descriptors are qualitative and most applicable to pathological staging. Possibly in the future, volumetric tumor measurement could enhance the current T descriptors.

In addition, the data demonstrate a difference in survival for node-negative versus node-positive patients. The difference between N1 and N2 disease is less clear, suggesting that additional study of the extent of lymph node involvement might yield improvements in the N-classification factor.

And finally the authors suggest that staging groups, especially for stages I and II disease, need to be reassessed. In the future, they say, "the addition of a larger group of patients with more advanced disease, staged clinically and managed nonsurgically may help determine whether stages III and IV should be classified into a and b subcategories."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our asbestos / mesothelioma section for the latest news on this subject. The lead author of this work is IASLC member Dr. Valerie Rusch (USA). Co-authors include IASLC members Dorothy Giroux (USA), Catherine Kennedy (Australia), Dr. Erico Ruffini (Italy), Dr. David Rice (USA), Dr. Harvey Pass (USA), Dr. Hisao Asamura (Japan), Dr. John Edwards (U.K.) and Dr. Walter Weder (Switzerland).

International Association for the Study of Lung Cancer

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

International Association for the Study of Lung Ca. "First Analysis Of IASLC Malignant Pleural Mesothelioma Database." Medical News Today. MediLexicon, Intl., 17 Oct. 2012. Web.
29 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'First Analysis Of IASLC Malignant Pleural Mesothelioma Database'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here